Marker Therapeutics, Inc. (MRKR) › Cash & EquivalentsMarker Therapeutics, Inc. (MRKR) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2017: $5.13M2018: $61.75M2019: $43.90M2020: $21.35M2021: $42.35M2022: $11.78M2023: $15.11M2024: $19.19M2025: $16.07M$16.07M2017Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$16.07M-16.3%2024$19.19M+27.0%2023$15.11M+28.3%2022$11.78M-72.2%2021$42.35M+98.3%2020$21.35M-51.4%2019$43.90M-28.9%2018$61.75M+1103.8%2017$5.13M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share